IFPMA announces Biogen Idec Inc. as new member

Published on: 23 August 2011

The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is pleased to announce that Biogen Idec Inc. has joined the Federation, thus bringing its membership up to 29 leading international companies and 44 national and regional industry associations.

IFPMA Director General Eduardo Pisani said: “We are delighted to welcome Biogen Idec, a pioneering biotech company, to the IFPMA. The company’s focus on finding innovative biotech solutions for patients only strengthens the Association’s credentials as representing the innovator pharmaceutical industry and its unique contribution to tackling global health issues.”

Biogen Idec is a global $4 billion Fortune 500 company. In addition to its headquarters in Weston, Massachusetts, Biogen Idec has offices in Argentina, Australia, Brazil, Canada, Japan, China, India and throughout Europe, operating in 29 countries with distribution partners in over 70.

Biogen Idec Inc. discovers, develops, manufactures and markets therapeutic products for the treatment of serious diseases with a focus on neurological disorders.

For further information on Biogen Idec, please go to www.biogenidec.com

Geneva, 23 August 2011


IFPMA represents research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry's 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.


Abigail Jones